AMENDMENT TO LICENSE AGREEMENTLicense Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT TO LICENSE AGREEMENT (the “Amendment”) is made and entered into effective as of April 29, 2008 (the “Amendment Effective Date”), by and between The Scripps Research Institute, a California nonprofit public benefit corporation (“Scripps”), and Sangamo BioSciences, Inc., a Delaware corporation (“Licensee”), having principal offices at 501 Canal Blvd., Suite A100, Richmond, CA 94804.
LICENSE AGREEMENT by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation and Sangamo Biosciences, Incorporated a Delaware corporationLicense Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances) • California
This License Agreement is entered into and made effective as of this 14th day of March, 2000, by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“Scripps”) located at 10550 North Torrey Pines Road, La Jolla, California 92037, and Sangamo Biosciences, Incorporated, a Delaware corporation, located at 501 Canal Street, Richmond, CA 94804 (“Licensee”), with respect to the facts set forth below.
FOURTH AMENDMENTLicense Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
This Amendment with the Effective Date February 10, 2000 is to the License Agreement dated May 9, 1996 between Sangamo BioSciences, Inc. and Massachusetts Institute of Technology, which was amended on December 10, 1997, December 2, 1998 and September 1, 1999.
FIRST AMENDMENT TO RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN SANGAMO BIOSCIENCES, INC. (“SANGAMO”) AND JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL (“JDRF”)Research, Development and Commercialization Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
This First Amendment (this “First Amendment”) to the Agreement of October 24, 2006 is made as of this 8th day of January 2010 (the “First Amendment Effective Date”) by and between Sangamo and JDRF. Capitalized terms used but not defined herein shall have the definition provided in this Agreement.
EIGHTH AMENDMENT TO PATENT LICENSE AGREEMENTPatent License Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
THIS EIGHTH AMENDMENT TO PATENT LICENSE AGREEMENT (the “Amendment”) is made and entered into effective as of February 1,. 2007 (the “Amendment Effective Date”), by and between Massachusetts Institute of Technology, a Massachusetts corporation (“M.I.T.”), and Sangamo BioSciences, Inc., a Delaware corporation (“Sangamo”) having principal offices at 501 Canal Blvd, Suite A100, Richmond, CA 94804.
FOURTH AMENDMENT OF THE RESEARCH AND COMMERCIAL LICENSE OPTION AGREEMENTResearch and Commercial License Option Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances) • Delaware
This FOURTH AMENDMENT OF THE RESEARCH AND COMMERCIAL LICENSE OPTION AGREEMENT (this “Fourth Amendment”) is made and effective as of January 8, 2010 (the “Fourth Amendment Effective Date”) by and between SANGAMO BIOSCIENCES, INC., a Delaware corporation having its principal place of business at Point Richmond Tech Center, 501 Canal Boulevard, Suite A100, Richmond, California 94804 (“Sangamo”), and DOW AGROSCIENCES LLC, a Delaware limited liability company having its principal place of business at 9330 Zionsville Road, Indianapolis, Indiana 46268 (“DAS”) (each of Sangamo and DAS being a “Party,” and collectively, the “Parties”).
SEVENTH AMENDMENT TO PATENT LICENSE AGREEMENTPatent License Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
THIS SEVENTH AMENDMENT TO PATENT LICENSE AGREEMENT (the “Amendment”) is made and entered into effective as of October 27, 2006 (the “Amendment Effective Date”), by and between Massachusetts Institute of Technology, a Massachusetts corporation (“M.I.T.”), and Sangamo BioSciences, Inc., a Delaware corporation (“Sangamo”) having principal offices at 501 Canal Blvd, Suite A100, Richmond, CA 94804.
SECOND AMENDMENTLicense Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
This Amendment with the Effective Date of December 2, 1998 is to the License Agreement dated May 9, 1996 between Sangamo BioSciences, Inc. and Massachusetts Institute of Technology, which was first amended December 10, 1997.
March 10, 2000 Ms. Nina M. Siegler Director, Office of Technology Transfer Johns Hopkins University 708N Wyman Park CenterLicense Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
SIXTH AMENDMENT TO PATENT LICENSE AGREEMENTPatent License Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
THIS SIXTH AMENDMENT TO PATENT LICENSE AGREEMENT (the “Amendment”) is made and entered into effective as of September 1, 2005 (the “Amendment Effective Date”), by and between Massachusetts Institute of Technology, a Massachusetts corporation (“M.I.T.”), and Sangamo BioSciences, Inc., a Delaware corporation (“Sangamo”) having principal offices at 501 Canal Blvd, Suite A100, Richmond, CA 94804.
FIRST AMENDMENT OF THE RESEARCH AND COMMERCIAL LICENSE OPTION AGREEMENTResearch and Commercial License Option Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
The Parties to the Research and Commercial License Option Agreement of October 1, 2005 (“Agreement”), SANGAMO BIOSCIENCES, INC., a Delaware corporation having its principal place of business at Point Richmond Tech Center, 501 Canal Boulevard, Suite A100, Richmond, California 94804 (“Sangamo”), and DOW AGROSCIENCES LLC, a Delaware limited liability company having its principal place of business at 9330 Zionsville Road. Indianapolis, Indiana 46268 (“DAS”), hereby amend the Agreement as follows:
AMENDMENT NO. 4 TO LICENSE AGREEMENTLicense Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
This Amendment No. 4 (“Amendment 4”), dated May 21, 2007 (“Amendment Effective Date”) amends the License Agreement (JHU Agrmt. # A00815), effective as of June 29, 1995 (the “Agreement”) between THE JOHNS HOPKINS UNIVERSITY (“JOHNS HOPKINS”) and SANGAMO BIOSCIENCES (“LICENSEE”).
THIRD AMENDMENTLicense Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
This Amendment with the Effective Date of September 1, 1999 is to the License Agreement dated May 9, 1996 between Sangamo BioSciences, Inc. and Massachusetts Institute of Technology, which was amended on December 10, 1997, and on December 2, 1998.
ContractResearch and Commercial License Option Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been redacted and are marked with a “[***]” in the place of the redacted language. The redacted information has been filed separately with the Commission.
Amendment No. 2 to the License Agreement between Johns Hopkins University and Sangamo BioSciences, Inc.License Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
This Amendment No. 2, dated July 26, 1999 (“Effective Date”) to the License Agreement dated June 29, 1995 concerning the licensing and other matters of patent properties referred to in Appendix A of the License Agreement, and in Amendment No. 1 dated June 1, 1998 (Dr. Srinivasan Chandrasegaran, Inventor) and other Patent Rights, is entered into between Johns Hopkins University, a not-for-profit educational institution having an address at 3400 North Charles Street, Baltimore, Maryland (“JOHNS HOPKINS” or “JHU”) and Sangamo BioSciences, Inc., a corporation of the State of Delaware and having a principal place of business at Point Richmond Tech Center, 501 Canal Blvd., Suite A100, Richmond, CA 94804 (“LICENSEE”).
FIFTH AMENDMENTLicense Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
This Amendment with the Effective Date of December 15, 2000 is to the License Agreement dated May 9, 1996 between Sangamo BioSciences, Inc. and Massachusetts Institute of Technology, which was amended on December 10, 1997, December 2, 1998, September 1, 1999 and February 10, 2000.
THIRD AMENDMENT OF THE RESEARCH AND COMMERCIAL LICENSE OPTION AGREEMENTResearch and Commercial License Option Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances) • Delaware
This THIRD AMENDMENT OF THE RESEARCH AND COMMERCIAL LICENSE OPTION AGREEMENT (this “Third Amendment”) is made and effective as of February 28, 2009 (the “Third Amendment Effective Date”) by and between SANGAMO BIOSCIENCES, INC., a Delaware corporation having its principal place of business at Point Richmond Tech Center, 501 Canal Boulevard, Suite A100, Richmond, California 94804 (“Sangamo”), and DOW AGROSCIENCES LLC, a Delaware limited liability company having its principal place of business at 9330 Zionsville Road, Indianapolis, Indiana 46268 (“DAS”) (each of Sangamo and DAS being a “Party,” and collectively, the “Parties”).
